keyword
MENU ▼
Read by QxMD icon Read
search

Non small cell lung cancer phase iii

keyword
https://www.readbyqxmd.com/read/28104361/igfbp-a-novel-target-of-lung-cancer
#1
REVIEW
QiongGe Hu, Yong Zhou, Kejing Ying, Wenjing Ruan
The insulin-like growth factor-1 receptor(IGF-1R) is a central component of lung cancer signal transduction pathways. A phase III study failed for carboplatin, paclitaxel, with or without figitumumab in first-line treating metastatic non-small cell lung cancer (NSCLC). There is an urgent need for a better understanding of signaling in IGF system. Insulin-like growth factor-binding proteins(IGFBPs) function as modulators for IGF signaling through sequestration of IGFs in serum and the extracellular fluid. IGFBPs can also act as transporters or modulators for IGF action and insulin action...
January 16, 2017: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/28103612/a-phase-iii-randomised-controlled-trial-of-erlotinib-vs-gefitinib-in-advanced-non-small-cell-lung-cancer-with-egfr-mutations
#2
J J Yang, Q Zhou, H H Yan, X C Zhang, H J Chen, H Y Tu, Z Wang, C R Xu, J Su, B C Wang, B Y Jiang, X Y Bai, W Z Zhong, X N Yang, Y L Wu
BACKGROUND: A phase III trial was conducted to compare the safety and efficacy of erlotinib with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations in exon 19 or 21. METHODS: Eligible patients were randomised to receive erlotinib (150 mg per day) or gefitinib (250 mg per day) orally until disease progression or unacceptable toxicity. We aimed to determine whether erlotinib is superior to gefitinib in efficacy...
January 19, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28089762/long-terms-results-of-a-trial-of-concurrent-chemotherapy-and-escalating-doses-of-radiation-for-unresectable-non-small-cell-lung-cancer-ncctg-n0028-alliance
#3
Steven E Schild, Shauna L Hillman, Angelina D Tan, Helen J Ross, William L McGinnis, Yolanda A Garces, David L Graham, Alex A Adjei, James R Jett
INTRODUCTION OR HYPOTHESIS: This phase I/II trial was originally designed to determine the maximally tolerated dose(MTD) of thoracic radiotherapy(TRT) as part of a combined modality approach. This report includes the long-term outcome of patients treated on this study. The phase II portion was never completed as RTOG-0617 opened before it was concluded. METHODS: The MTD was defined as 74Gy in 37 fractions in this study. Twenty-five patients with unresectable non-small cell lung cancer(NSCLC) were treated with 2Gy daily fractions and concurrent weekly carboplatin and paclitaxel...
January 12, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28073946/a-randomized-phase-iii-trial-of-comparing-two-dose-fractionations-stereotactic-body-radiotherapy-sbrt-for-medically-inoperable-stage-ia-non-small-cell-lung-cancer-or-small-lung-lesions-clinically-diagnosed-as-primary-lung-cancer-japan-clinical-oncology-group
#4
EDITORIAL
Tomoki Kimura, Yasushi Nagata, Junko Eba, Shuichi Ozawa, Satoshi Ishikura, Taro Shibata, Yoshinori Ito, Masahiro Hiraoka, Yasumasa Nishimura
A randomized Phase III trial commenced in Japan in February 2016. Currently, 42 Gy in four fractions of stereotactic body radiotherapy prescribed at the D95% of the planning target volume, which is considered equal to the commonly used 48 Gy in four fractions at the isocenter using an old dose calculation algorithm, is the standard treatment in Japan for medically inoperable Stage IA non-small cell lung cancer and small lung lesions clinically diagnosed as primary lung cancer. This study aims to examine the superiority of 55 Gy in four fractions over 42 Gy in four fractions...
January 9, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28069259/sex-differences-in-hazard-ratio-during-drug-treatment-of-non-small-cell-lung-cancer-in-major-clinical-trials-a-focused-data-review-and-meta-analysis
#5
Lishi Wang, Yanhong Cao, Mingji Ren, Amei Chen, Jinglin Cui, DiaJun Sun, Weikuan Gu
PURPOSE: Understanding how sex impacts the efficacy of anticancer agents is a crucial step toward personalized and precision medicine. This review and meta-analysis evaluated sex differences in hazard ratios (HRs) of progression-free survival and overall survival in representative Phase III clinical trials of non-small-cell lung cancer (NSCLC). METHODS: Data were extracted from 24 large-scale clinical trials that included 12,000 male and 7000 female patients. The data were examined for HR differences between subgroups by sex, smoking status, and age, and for potential sex-smoking status, sex-age, and sex-drug interactions, during cancer treatment...
January 6, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28067062/developments-in-pharmacotherapy-for-treating-metastatic-non-small-cell-lung-cancer
#6
Antonio Rossi, Paola Claudia Sacco, Giuseppe Santabarbara, Assunta Sgambato, Francesca Casaluce, Giovanni Palazzolo, Paolo Maione, Cesare Gridelli
Most patients with non-small cell lung (NSCLC), including squamous cell carcinoma, adenocarcinoma and large cell carcinoma, have advanced disease at diagnosis and systemic therapy is the standard-of-care. About 20% of Caucasian patients are affected by an oncogene-addicted advanced NSCLC for which correspondent inhibitors are available. Areas covered: The main state-of-the-art synthetic anticancer drugs in the groups of chemotherapeutics, epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors for NSCLC treatment, are reviewed and discussed from phase III randomized practice-changing trials onwards...
January 8, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28057177/les-inhibiteurs-des-points-de-contr%C3%A3-le-immunitaire-dans-le-cancer-bronchique-non-%C3%A3-petites-cellules-de-stade-avanc%C3%A3
#7
Elizabeth Fabre, Nicola Pécuchet, Jacques Cadranel
IMMUNE CHECKPOINT INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER: T-cell-directed strategies represent currently a major advance in the treatment of advanced non-small-cell lung cancer, regarding their efficacy and tolerance. Nivolumab and pembrolizumab, two monoclonal antibodies targeting programmed cell death protein 1 (PD-1) have shown their efficacy in phase III studies. Several other drugs are developed and the benefit of association is being evaluated. In this article, we propose to summarize the clinical development of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer...
November 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/28045649/cost-effectiveness-of-pemetrexed-in-combination-with-cisplatin-as-first-line-treatment-for-patients-with-advanced-non-squamous-non-small-cell-lung-cancer-in-spain
#8
Jonathan González García, Fernando Gutiérrez Nicolás, Gloria Julia Nazco Casariego, Cristina Valcárcel Nazco, Jose Norberto Batista López, Juana Oramas Rodríguez
INTRODUCTION: Lung cancer is the third most frequent neoplastic tumour in Spain, with around 27 000 new cases diagnosed per year; 80-95% of these are non-small-cell cancer (NSCLC), and the majority of cases are diagnosed in advanced stages of the disease, and for this reason it is one of the oncologic conditions with higher mortality rates (21.4% mean survival at 5 years). The main treatment regimens used for first-line treatment of NSCLC are: cisplatin/pemetrexed (cis/pem), cisplatin/gemcitabine/ bevacizumab (cis/gem/bev), and carboplatin/paclitaxel/ bevacizumab (carb/pac/bev)...
January 1, 2017: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/28043144/association-of-egfr-and-kras-mutations-with-expression-of-p-akt-dr5-and-dcr1-in-non-small-cell-lung-cancer
#9
X D Zhao, H B Deng, C L Lu, Y X Bao, X Lu, L L Deng
The activation of AKT is one of the causes of resistance to epidermal growth factor receptor (EGFR)- tyrosine kinase inhibitors (TKIs). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) combines with related receptors to trigger apoptosis or protect the cells against TRAIL apoptosis. This research focused on the association of EGFR and KRAS mutations with expression of AKT, p-AKT, DR5 and DcR1 in non-small cell lung cancer. 82 NSCLC patients were included in the study. xTAG liquichip techonolgy (xTAG-LCT) was applied to investigate the genetic mutation of EGFR and KRAS, Quantitative Real-time PCR was used to test the mRNA expression of AKT, DR5 and DcR1 and Western Blot was applied to test the protein expression of AKT, p-AKT, DR5, and DcR1...
January 3, 2017: Neoplasma
https://www.readbyqxmd.com/read/28028730/exposure-response-and-tumor-growth-inhibition-analyses-of-the-monovalent-anti-c-met-antibody-onartuzumab-metmab-in-the-second-and-third-line-non-small-cell-lung-cancer
#10
Kelong Han, Pascal Chanu, Fredrik Jonsson, Helen Winter, René Bruno, Jin Jin, Mark Stroh
The phase III trial comparing onartuzumab + erlotinib vs. erlotinib in the second- and third-line non-small cell lung cancer (NSCLC) did not meet its primary endpoint of overall survival (OS). The objective was to assess whether doses higher than the phase III dose (15 mg/kg) might yield better efficacy without compromising the safety profile. Data were from 636 patients from the phase II and III NSCLC studies. Tumor growth inhibition (TGI) models were fit to longitudinal tumor size data to estimate individual TGI metrics including time to tumor re-growth (TTG)...
December 27, 2016: AAPS Journal
https://www.readbyqxmd.com/read/28024698/interpreting-survival-data-from-clinical-trials-of-surgery-versus-stereotactic-body-radiation-therapy-in-operable-stage-i-non-small-cell-lung-cancer-patients
#11
Pamela Samson, Kathleen Keogan, Traves Crabtree, Graham Colditz, Stephen Broderick, Varun Puri, Bryan Meyers
OBJECTIVES: To identify the variability of short- and long-term survival outcomes among closed Phase III randomized controlled trials with small sample sizes comparing SBRT (stereotactic body radiation therapy) and surgical resection in operable clinical Stage I non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Clinical Stage I NSCLC patients who underwent surgery at our institution meeting the inclusion/exclusion criteria for STARS (Randomized Study to Compare CyberKnife to Surgical Resection in Stage I Non-small Cell Lung Cancer), ROSEL (Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer), or both were identified...
January 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28017787/randomized-phase-iii-trial-of-erlotinib-versus-docetaxel-in-patients-with-advanced-squamous-cell-non-small-cell-lung-cancer-failing-first-line-platinum-based-doublet-chemotherapy-stratified-by-veristrat-good-versus-veristrat-poor-the-european-thoracic-oncology
#12
Solange Peters, Rolf A Stahel, Urania Dafni, Santiago Ponce Aix, Bartomeu Massutí, Oliver Gautschi, Linda Coate, Ana López Martín, Robbert van Heemst, Thierry Berghmans, Peter Meldgaard, Manuel Cobo Dols, Javier Garde Noguera, Alessandra Curioni-Fontecedro, Daniel Rauch, Michael T Mark, Sinead Cuffe, Bonne Biesma, Arjen Mj van Henten, Óscar Juan Vidal, Ramón Palmero Sanchez, José Carlos Villa Guzmán, Ricardo Collado Martin, Sergio Peralta, Amelia Insa, Yvonne Summers, István Láng, Anne Horgan, Fortunato Ciardiello, Sander de Hosson, Remge Pieterman, Harry Jm Groen, Paul M van den Berg, Christoph C Zielinski, Yojena Chittazhathu Kurian Kuruvilla, Adriana Gasca-Ruchti, Marie Kassapian, Silvia Novello, Valter Torri, Zoi Tsourti, Vanesa Gregorc, Egbert F Smit
INTRODUCTION: Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the Veristrat test in second-line therapy of NSCLC, classifying patients as either Veristrat "good" or "poor". EMPHASIS-lung aimed at exploring this predictive effect in patients with squamous cell NSCLC. The trial closed prematurely due to low accrual and results from other trials. Our analysis includes an exploratory combined analysis with results from the PROSE trial...
December 22, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28012777/sequential-administration-of-a-mva-based-muc1-cancer-vaccine-and-the-tlr9-ligand-litenimod-li28-improves-local-immune-defense-against-tumors
#13
Emmanuelle Schaedler, Christelle Remy-Ziller, Julie Hortelano, Nadine Kehrer, Marie-Christine Claudepierre, Tanja Gatard, Christopher Jakobs, Xavier Préville, Antoine F Carpentier, Karola Rittner
TG4010 is an immunotherapeutic vaccine based on Modified Vaccinia virus Ankara (MVA) encoding the human tumor-associated antigen MUC1 and human IL-2. In combination with first-line standard of care chemotherapy in advanced metastatic non-small-cell lung cancer (NSCLC), repeated subcutaneous injection of TG4010 improved progression-free survival in phase 2b clinical trials. In preclinical tumor models, MVATG9931, the research version of TG4010, conferred antigen-specific responses against the weak antigen human MUC1...
December 21, 2016: Vaccine
https://www.readbyqxmd.com/read/27997007/-new-perspectives-in-second-line-treatment-in-non-squamous-non-small-cell-lung-cancer
#14
Francesco Grossi
The treatment options for patients with non-squamous non-small cell lung cancer (NSCLC) in second-line have been limited for a long time. Docetaxel, pemetrexed and erlotinib are the standard second-line treatment. Docetaxel is frequently used although it is associated with an unfavorable safety profile. Recently, the results from the trial CheckMate 057 with nivolumab, an anti-PD-1 inhibitor, has increased the therapeutic options for patients with non-squamous NSCLC in the second-line setting. The results of this randomized phase III trial comparing nivolumab vs docetaxel have deeply changed our current clinical practice...
December 2016: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/27997006/-nivolumab-in-second-line-treatment-of-squamous-non-small-cell-lung-cancer
#15
Filippo De Marinis, Antonio Passaro
The treatment of non-small cell lung cancer (NSCLC) is changing dramatically in the last period, considering both non-squamous and squamous disease. In the last five years, the identification of different molecular predictive biomarker (e.g., EGFR, ALK e ROS1) and the utilize of new chemotherapy agents associated or not with antiangiogenics agents (e.g., bevacizumab and nintedanib), allowed the improvement of survival and related responses to these treatments. However, these advances, did not allow an improvement of the same endpoints in the management of NSCLC with squamous cell histology (SCC), where until very recently, docetaxel in monotherapy remained as a corner stone treatment for the second line, although associated with an unfavorable toxicity profile...
December 2016: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/27995307/phase-i-study-of-nab-paclitaxel-plus-carboplatin-and-concurrent-thoracic-radiotherapy-in-patients-with-locally-advanced-non-small-cell-lung-cancer
#16
Kyoichi Kaira, Yoshio Tomizawa, Hisao Imai, Reiko Sakurai, Masana Matsuura, Akihiro Yoshii, Mai Ochiai, Mie Kotake, Takeshi Ebara, Jun-Ichi Saitoh, Noriaki Sunaga, Koichi Minato, Ryusei Saito, Takeshi Hisada
BACKGROUND: The aim of our study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin in combination with thoracic radiotherapy for patients with locally advanced stage III non-small cell lung cancer (NSCLC). METHODS: Weekly nab-paclitaxel plus carboplatin was administered intravenously for 6 weeks. Doses of each drug were planned as follows: level 1, 40/2; level 2, 60/2; level 3, 80/2 (nab-paclitaxel [mg/m(2)]/carboplatin [area under the plasma concentration time curve mg/ml/min])...
December 19, 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27987591/nintedanib-plus-pemetrexed-versus-placebo-plus-pemetrexed-in-patients-with-relapsed-or-refractory-advanced-non-small-cell-lung-cancer-lume-lung-2-a-randomized-double-blind-phase-iii-trial
#17
Nasser H Hanna, Rolf Kaiser, Richard N Sullivan, Osvaldo Rudy Aren, Myung-Ju Ahn, Beatrice Tiangco, Isabelle Voccia, Joachim von Pawel, Vladimir Kovcin, Jason Agulnik, Birgit Gaschler-Markefski, José Barrueco, Patricia Sikken, Charles Schloss, Joo-Hang Kim
OBJECTIVES: LUME-Lung 2 investigated the efficacy/safety of nintedanib plus pemetrexed in patients with pretreated non-squamous non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity...
December 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27987585/maintenance-erlotinib-versus-erlotinib-at-disease-progression-in-patients-with-advanced-non-small-cell-lung-cancer-who-have-not-progressed-following-platinum-based-chemotherapy-iuno-study
#18
Saulius Cicènas, Sarayut Lucien Geater, Petar Petrov, Yevgeniy Hotko, Gregory Hooper, Fan Xia, Nadejda Mudie, Yi-Long Wu
OBJECTIVE: The phase III IUNO trial assessed the benefit of maintenance erlotinib versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had not progressed following four cycles of platinum-based chemotherapy. MATERIALS AND METHODS: Patients had stage IIIB/IV NSCLC, no known epidermal growth factor receptor (EGFR)-activating mutation, and objective response or disease stabilization after platinum-based induction chemotherapy...
December 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27978552/comparison-of-concurrent-use-of-thoracic-radiation-with-either-carboplatin-paclitaxel-or-cisplatin-etoposide-for-patients-with-stage-iii-non-small-cell-lung-cancer-a-systematic-review
#19
Conor E Steuer, Madhusmita Behera, Vinicius Ernani, Kristin A Higgins, Nabil F Saba, Dong M Shin, Suchita Pakkala, Rathi N Pillai, Taofeek K Owonikoko, Walter J Curran, Chandra P Belani, Fadlo R Khuri, Suresh S Ramalingam
Importance: The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (NSCLC) are carboplatin-paclitaxel and cisplatin-etoposide. There are no prospective comparisons of these 2 regimens in this setting. Objective: To conduct a systematic review of published trials to compare outcomes and toxic effects between cisplatin-etoposide and carboplatin-paclitaxel in patients with non-small-cell lung cancer receiving thoracic radiation...
December 15, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27976752/erratum-to-the-sabrtooth-feasibility-trial-protocol-a-study-to-determine-the-feasibility-and-acceptability-of-conducting-a-phase-iii-randomised-controlled-trial-comparing-stereotactic-ablative-radiotherapy-sabr-with-surgery-in-patients-with-peripheral-stage
#20
M P Snee, L McParland, F Collinson, C M Lowe, A Striha, D R Baldwin, B Naidu, D Sebag-Montefiore, W M Gregory, J Bestall, J Hewison, S Hinsley, K N Franks
[This corrects the article DOI: 10.1186/s40814-016-0046-2.].
2016: Pilot and Feasibility Studies
keyword
keyword
64374
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"